Floatz logo

zg2001 tosilate tablets

KRAS Mutation-Related Tumors

Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the KRAS Mutation-Related Tumors cohort.

Asset / SponsorPhaseRating
Binimetinib
Abramson Cancer Center at Penn Medicine
Phase 2B
Hydroxychloroquine
Abramson Cancer Center at Penn Medicine
Phase 2B
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 25 →

Same molecule, other indications

zg2001 tosilate tablets is also rated in:

neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →